Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
Gain Therapeutics (Nasdaq: GANX) announced three presentations at Neuroscience 2024, showcasing preclinical data for GT-02287, their lead drug candidate for Parkinson's disease. The event will be held in Chicago from October 5-9, 2024.
Two late-breaking posters will be presented:
- GT-02287's prevention of Tau accumulation in a cellular model
- GT-02287's disease-modifying capacity in both GBA1 and idiopathic Parkinson's disease models
A third presentation will focus on GT-02287's improvement of mitochondrial function and neuroprotective effects in GBA1-Parkinson's disease models. These studies were conducted in collaboration with researchers from Switzerland, supported by an Innosuisse-Swiss Innovation Agency grant.
Gain Therapeutics (Nasdaq: GANX) ha annunciato tre presentazioni a Neuroscience 2024, mostrando dati preclinici per GT-02287, il loro principale candidato farmaco per il morbo di Parkinson. L'evento si terrà a Chicago dal 5 al 9 ottobre 2024.
Verranno presentati due poster in late-breaking:
- La prevenzione dell'accumulo di Tau in un modello cellulare da parte di GT-02287
- La capacità di modifica della malattia di GT-02287 sia in modelli di Parkinson di tipo GBA1 che idiopatico
Una terza presentazione si concentrerà sul miglioramento della funzione mitocondriale e degli effetti neuroprotettivi di GT-02287 in modelli di malattia di Parkinson GBA1. Questi studi sono stati condotti in collaborazione con ricercatori svizzeri, supportati da un finanziamento dell'Innosuisse-Swiss Innovation Agency.
Gain Therapeutics (Nasdaq: GANX) anunció tres presentaciones en Neuroscience 2024, mostrando datos preclínicos para GT-02287, su principal candidato a fármaco para la enfermedad de Parkinson. El evento se llevará a cabo en Chicago del 5 al 9 de octubre de 2024.
Se presentarán dos carteles de última hora:
- Prevención de la acumulación de Tau en un modelo celular por parte de GT-02287
- Capacidad modificadora de la enfermedad de GT-02287 en modelos de Parkinson tanto de tipo GBA1 como idiopático
Una tercera presentación se centrará en la mejora de la función mitocondrial y los efectos neuroprotectores de GT-02287 en modelos de enfermedad de Parkinson GBA1. Estos estudios se llevaron a cabo en colaboración con investigadores de Suiza, apoyados por una subvención de la Agencia Suiza de Innovación Innosuisse.
Gain Therapeutics (Nasdaq: GANX)는 Neuroscience 2024에서 GT-02287의 전임상 데이터를 선보이며 세 가지 발표를 한다고 발표했습니다. 이들은 파킨슨병의 주요 약물 후보입니다. 이 행사는 2024년 10월 5일부터 9일까지 시카고에서 열릴 예정입니다.
두 개의 긴급 발표 포스터가 있을 예정입니다:
- GT-02287의 세포 모델에서의 타우 축적 예방
- GT-02287의 GBA1 및 특발성 파킨슨병 모델에서의 질병 수정 능력
세 번째 발표는 GBA1-파킨슨병 모델에서 GT-02287의 미토콘드리아 기능 개선 및 신경 보호 효과에 초점을 맞출 것입니다. 이 연구들은 스위스의 연구자들과 협력하여 수행되었으며, 스위스 혁신 기관 Innosuisse의 지원을 받았습니다.
Gain Therapeutics (Nasdaq: GANX) a annoncé trois présentations lors de Neuroscience 2024, mettant en avant des données précliniques pour GT-02287, leur principal candidat médicament pour la maladie de Parkinson. L'événement se tiendra à Chicago du 5 au 9 octobre 2024.
Deux posters de dernière minute seront présentés :
- La prévention de l'accumulation de Tau dans un modèle cellulaire par GT-02287
- La capacité de modification de la maladie de GT-02287 dans les modèles de Parkinson de type GBA1 et idiopathique
Une troisième présentation se concentrera sur l'amélioration de la fonction mitochondriale et des effets neuroprotection de GT-02287 dans les modèles de maladie de Parkinson GBA1. Ces études ont été menées en collaboration avec des chercheurs de Suisse, soutenues par une subvention de l'Agence suisse pour l'innovation Innosuisse.
Gain Therapeutics (Nasdaq: GANX) hat drei Präsentationen auf der Neuroscience 2024 angekündigt, in denen präklinische Daten für GT-02287, ihr wichtigster Medikamentenkandidat für Parkinson-Krankheit, vorgestellt werden. Die Veranstaltung findet vom 5. bis 9. Oktober 2024 in Chicago statt.
Es werden zwei Spätankündigungen präsentiert:
- Die Prävention der Tau-Akkumulation in einem Zellmodell durch GT-02287
- Die krankheitsmodifizierende Fähigkeit von GT-02287 in GBA1- und idiopathischen Parkinson-Modellen
Eine dritte Präsentation wird sich auf die Verbesserung der Mitochondrienfunktion und die neuroprotektiven Effekte von GT-02287 in GBA1-Parkinson-Modellen konzentrieren. Diese Studien wurden in Zusammenarbeit mit Forschern aus der Schweiz durchgeführt und von einem Innosuisse-Schweizer Innovationsagentur-Stipendium unterstützt.
- None.
- None.
BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations, including two late-breakers, at Neuroscience 2024 featuring preclinical data supporting development of GT-02287, the Company’s clinical stage lead drug candidate, in Parkinson’s disease with or without a GBA1 mutation. Neuroscience 2024, the Society for Neuroscience’s premier event, will be held at McCormick Place Convention Center in Chicago, IL from October 5-9, 2024.
Poster Presentations Details
Title: GT-02287, a GCase modulator and Gain Therapeutics’ PD drug candidate prevents Tau accumulation in a cellular model
Presenting author: Natalia Perez-Carmona (Gain Therapeutics)
Session: Theme C Late-Breaking Posters
Presentation Date/Time: Sunday, October 6, 2024, 1 - 2 p.m. ET
This study was done in collaboration with scientists in the group of Professor Paolo Paganetti at the Laboratories for Translational Research of the Ente Ospedaliero Cantonale (LRT-EOC) in Bellinzona, Switzerland. This study was conducted under the support of an Innosuisse-Swiss Innovation Agency grant with the LRT-EOC and the Università della Svizzera italiana-affiliated Institute for Research in Biomedicine in Bellinzona, Switzerland.
Title: GT-02287, a clinical stage GCase regulator, demonstrates disease modifying capacity in both GBA1 and idiopathic Parkinson’s disease models
Presenting author: Joanne Taylor (Gain Therapeutics)
Session: Theme C Late-Breaking Posters
Presentation Date/Time: Sunday, October 6, 2024, 3 - 4 p.m. ET
Title: GT-02287, a clinical stage GCase regulator, improves mitochondrial function and provides a neuroprotective effect in GBA1-Parkinson's disease models
Presenting author: Natalia Perez-Carmona (Gain Therapeutics)
Session: Parkinson’s Disease: Neuroprotective Mechanisms
Presentation Date/Time: Sunday, October 6, 2024, 10 - 11 a.m. ET
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric protein modulator that restores the function of the lysosomal protein enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function and cognitive performance. Additionally, GT-02287 significantly reduced plasma neurofilament light chain (NfL) levels, an emerging biomarker for neurodegeneration.
Compelling preclinical data in mouse models of GBA1-PD, including that presented at FENS Forum 2024 in June describing improvement in cognitive performance in addition to motor performance after administration of GT-02287, suggests that GT-02287 may have the potential to slow the progression of Parkinson’s disease.
Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 for the treatment of Parkinson’s disease with or without a GBA1 mutation, is currently being evaluated in a Phase 1 clinical trial.
Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-powered physics-based models, the company’s Magellan™ drug discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of over five trillion compounds to identify and select suitable small molecule hits for experimental validation.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended June 30, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com
Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9265
FAQ
What is Gain Therapeutics presenting at Neuroscience 2024?
When and where is Neuroscience 2024 taking place?
What are the key findings of GT-02287 presented by Gain Therapeutics (GANX)?
Who collaborated with Gain Therapeutics (GANX) on the GT-02287 studies?
